Oxford Vaccine is 70 Percent Effective: The Lancet
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
The first full peer-review analysis of the Oxford-AstraZeneca vaccine trial results was published in Journal The Lancet suggests it is safe and about 70 percent effective. Still, experts say the vaccine seems likely to be approved, despite some confusion in the results and lower levels of protection.

The initial results showed that the vaccine was 62.1 per cent efficacious in participants who received two standard doses, while it had 90 per cent efficacy in participants who received a low dose followed by a standard dose. The findings were that there was 70 per cent overall efficacy.

Less than 6 percent of UK trial participants were given the lower dose regimen and none of them was aged over 55, meaning more research will be needed to investigate the vaccine’s efficacy in older people who are particularly susceptible to COVID-19.

21 days after the first dose but it is not clear in which trial from which country there were ten cases hospitalised for COVID-19, two were classified as severe COVID-19, including one death.

The researchers concluded that ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials.

Source:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext#seccestitle210
S●●●●r A●●z and 1 others like this1 share
Like
Comment
Share